Why TG Therapeutics Is Tumbling 15% Today

After TG Therapeutics, Inc.'s(NASDAQ: TGTX) discussion with the FDA regarding its most advanced clinical-stage drug raised concerns over a speedy approval, shares in the company are losing 15% of their value as of 2 pm EDT.

TG Therapeutics reported earlier this year that adding its TG-1101, or ublituximab, to AbbVie Inc.'s (NYSE: ABBV) and Johnson & Johnson's (NYSE: JNJ) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in patients with high-risk chronic lymphocytic leukemia. The complete response rate to the two-drug combination was 7%. These results matched up favorably to the 45% ORR and 0% complete response rates for Imbruvica on its own.

IMAGE SOURCE: GETTY IMAGES.

Source: Fool.com